Angioplasty

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and symptoms. Mavacamten is the first myosin inhibitor drug of its class. Presented virtually at the European Society of Cardiology 2020 Congress (ESC&nbsp;2020) and published simultaneously in The Lancet, the EXPLORER-HCM study showed that 37% of patients who received<a href="https://solaci.org/en/2020/09/03/esc-2020-new-drug-improves-functional-capacity-in-hypertrophic-cardiomyopathy/" title="Read more" >...</a>

ESC 2020 | Fibrilación auricular y control del ritmo ¿Una cuestión de tiempo?

ESC 2020 | Atrial Fibrillation and Rhythm Control: A Matter of Time?

Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events compared against the usual treatment of frequency control.&nbsp; These data come from the EAST-AFNET 4 trial recently presented at ESC 2020, simultaneously published in NEJM. These data suggest that we should offer patients early rhythm control therapy to<a href="https://solaci.org/en/2020/09/02/esc-2020-atrial-fibrillation-and-rhythm-control-a-matter-of-time/" title="Read more" >...</a>

The Fellow&#8217;s Corner | 1st Clinical Case: All That Glitters Is Not Gold

We present the first clinical case in the section “The Fellow’s Corner”, aimed at fellows in Latin America who wish to learn and always be up to date in interventional cardiology. Leave your thoughts in the comment section of this article and join the conversation! Case Authors: Jair Suriano Martins (ARG), Leonardo Ripa (ARG). Moderator:<a href="https://solaci.org/en/2020/08/26/the-fellows-corner-1st-clinical-case-all-that-glitters-is-not-gold/" title="Read more" >...</a>

Claves para mejorar la productividad en la sala de cateterismo

Early Activation to Speed-Up Treatment of Infarcted Patients

Cath lab activation—and everything that entails—within 20&nbsp;minutes was associated with the target of performing primary angioplasty in under 2&nbsp;hours in at least 75% of patients. Historically, door-to-balloon time was measured, which provided a rough idea of where there could be flaws to fix. This is particularly true in the case of patients who need to<a href="https://solaci.org/en/2020/08/15/early-activation-to-speed-up-treatment-of-infarcted-patients/" title="Read more" >...</a>

The Most Read Scientific Articles of July

The Most Read Scientific Articles of July in Interventional Cardiology

01- SOLACI PERIPHERAL | 2nd Clinical Case: Juxtarenal Abdominal Aortic Aneurysm SOLACI’s Department of Peripheral Endovascular Interventions&nbsp;brings a new challenging clinical case for the whole Latin American medical community so as to continue fostering and sharing scientific knowledge and experience among peers. Read more HERE 02- EuroPCR 2020 | A Trick to Find the Perfect<a href="https://solaci.org/en/2020/08/10/the-most-read-scientific-articles-of-july-in-interventional-cardiology/" title="Read more" >...</a>

Evidencia randomizada sobre la utilidad del yoga en la rehabilitación cardíaca

Randomized Evidence on the Helpfulness of Yoga for Cardiac Rehabilitation

This work brings us evidence that yoga-based cardiac rehabilitation improves how patients feel about their health and reduces the time it takes them to resume the activities they could perform before experiencing an infarction. That is important information with impeccable timing. The COVID-19 pandemic has interrupted most of the assistance we offer to cardiovascular patients,<a href="https://solaci.org/en/2020/07/24/randomized-evidence-on-the-helpfulness-of-yoga-for-cardiac-rehabilitation/" title="Read more" >...</a>

Disnea y oclusiones totales crónicas: un síntoma que podemos aliviar (o al menos intentarlo)

Subintimal Re-Entry in CTO Improves Outcomes

Courtesy of Dr. Carlos&nbsp;Fava. Chronic total occlusions (CTO) are still one of the greatest challenges in our field, thus forcing the development of different complex strategies to resolve them. Additionally, the use of imaging techniques during these procedures has improved long-term results. The CONSISTENT CTO (Conventional Antegrade Versus Sub-Intimal Synergy Stenting in Chronic Total Occlusions)<a href="https://solaci.org/en/2020/07/17/subintimal-re-entry-in-cto-improves-outcomes/" title="Read more" >...</a>

Historia natural de la infección asintomática por COVID-19

European Association of Percutaneous Cardiovascular Interventions Position Statement During the Pandemic

This document emerges from the assembly of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Acute Cardiovascular Care Association (ACVC). Both associations gathered their most prominent experts, including people who worked in the European areas most affected by COVID-19. Their aim was to modify diagnostic and therapeutic algorithms to adapt the evidence collected<a href="https://solaci.org/en/2020/07/16/european-association-of-percutaneous-cardiovascular-interventions-position-statement-during-the-pandemic/" title="Read more" >...</a>

EuroPCR 2020 | A Trick to Find the Perfect Projection to Treat Ostia or Bifurcation Lesions

The trick is to avoid testing empirically more to the right or to the left, a more caudal or cranial angular, and check what a multislice computed tomography suggests. The increase in coronary computed tomography imaging studies—due to guideline recommendations, practicality, and patient comfort—means that we frequently have these data in the cath lab even<a href="https://solaci.org/en/2020/07/14/europcr-2020-a-trick-to-find-the-perfect-projection-to-treat-ostia-or-bifurcation-lesions/" title="Read more" >...</a>

EuroPCR 2020 | FABOLUS FASTER: buscando la inhibición plaquetaria más potente y rápida

EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition

This small study tested the pharmacodynamic effects of several antiplatelet agents. It concluded that tirofiban (Aggrastat) provides “more potent and consistent” inhibition of platelet aggregation compared with cangrelor in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Thirty minutes after the initiation of treatment, there was a nearly threefold difference between tirofiban and cangrelor<a href="https://solaci.org/en/2020/07/10/europcr-2020-fabolus-faster-in-the-quest-for-the-fastest-most-potent-platelet-inhibition/" title="Read more" >...</a>

Top